CardioMEMS
- Company typePrivate
- Founded2014
- HeadquartersAtlanta, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
CardioMEMS firmographics
Firmographics- Name
- CardioMEMS
- Legal name
- CardioMEMS
- Website
- https://cardiomems.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
CardioMEMS industry classification
Industry- Product category
- Implantable Cardiac Hemodynamic Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industries
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Cardiology Telemedicine Platforms (HLALAGAB)
Keywords
Where CardioMEMS is headquartered
LocationHeadquarters
- HQ city
- Atlanta
- HQ country
- United States
- HQ region
- North America
Markets served
CardioMEMS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Revenue model
- Implantable Device Sales: The CardioMEMS HF System is sold as a medical device comprising the implantable sensor and patient electronics. Revenue is generated from device sales to hospitals and healthcare facilities where implantation procedures are performed.
- Remote Monitoring Services: Ongoing monitoring services through the Merlin.net portal provide clinicians with patient data and notifications. The system is covered by Medicare and Medicare Advantage, indicating recurring reimbursement for monitoring activities.
- Clinical Procedure Revenue: The implantation procedure generates professional and facility fees. The system is indicated for NYHA Class II or III heart failure patients who have been hospitalized or have elevated natriuretic peptides.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | CardioMEMS HF System with Medicare coverage |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CardioMEMS product offering
Product offeringCore offering
CardioMEMS develops and manufactures the CardioMEMS HF System, an FDA-approved wireless implantable pulmonary artery (PA) pressure sensor that, together with a Patient Electronics System and the Merlin.net Patient Care Network portal, enables remote hemodynamic monitoring of NYHA Class II/III heart failure patients (both HFpEF and HFrEF). The system transmits PA pressure and heart rate data from the patient's home to clinicians, supporting presymptomatic intervention to reduce heart failure hospitalizations and mortality. CardioMEMS sells the platform to hospitals, cardiology practices, and heart failure centers through Abbott's cardiovascular division and is reimbursed by Medicare and Medicare Advantage.
Product overview
The CardioMEMS HF System is a single unified product — a remote hemodynamic monitoring platform for heart failure patients. It consists of the implantable CardioMEMS sensor (measuring pulmonary artery pressure and heart rate), the Patient Electronics System (reader/pillow for data transmission), and the Merlin.net Patient Care Network (cloud-based portal for clinicians to review patient data). The system supports both HFpEF (heart failure with preserved ejection fraction) and HFrEF (heart failure with reduced ejection fraction) patients, enabling physicians to make therapy adjustments through telemonitoring and intervene early before hospitalization is required. CardioMEMS was acquired by Abbott and is covered by Medicare and Medicare Advantage.
Differentiator
Problem solved
Functional benefit
Brands
- CardioMEMS HF System: Remote pulmonary artery pressure monitoring platform for heart failure patients (HFpEF and HFrEF)
Products and services
- CardioMEMS HF System
Quantifiable outcome
- Reduces heart failure-related hospitalizations
- +3 more outcomes
Companies that use CardioMEMS
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
CardioMEMS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CardioMEMS partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Abbott LaboratoriesflagshipCardioMEMS was acquired by Abbott Labs and now operates as part of Abbott's cardiovascular division. The acquisition provided Abbott with a leading remote hemodynamic monitoring platform for heart failure management, complementing their HeartMate 3 circulatory support device. CardioMEMS is now monitoring over 35,000 heart failure patients across 20 countries under Abbott's ownership.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
CardioMEMS competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is a broad cardiovascular incumbent with multiple heart failure and cardiac diagnostic offerings, including implantable cardiac monitors (Reveal LINQ). It overlaps with CardioMEMS in the broader heart failure diagnostics and remote monitoring category, though not as a direct PA pressure competitor.
- Edwards Lifesciences: Edwards Lifesciences is a major cardiovascular player with heart failure diagnostics and monitoring technologies including the Acumen platform. It is a broad incumbent competing for hospital budgets and hemodynamic monitoring decision-making in cardiac surgery and heart failure settings.
- GE HealthCare: GE HealthCare provides patient monitoring solutions and connected care platforms used by hospitals, including hemodynamic and cardiac monitoring tools. It is a broad incumbent with overlapping institutional channels and competitive positioning in the hospital-based monitoring market.
- Boston Scientific: Boston Scientific is a diversified cardiovascular device manufacturer with heart failure and cardiac diagnostics offerings. It is a broad incumbent in the cardiovascular space with overlapping institutional relationships and channels to cardiology practices served by CardioMEMS.
Direct peers
- Endotronix: Endotronix develops the Cordella PA pressure sensor system, a directly competing implantable pulmonary artery pressure monitor for heart failure management. It is the most direct head-to-head competitor to CardioMEMS in remote hemodynamic monitoring for HF patients.
- FIRE1 (Foundry Innovation & Research 1): FIRE1 is developing an implantable sensor for remote heart failure monitoring, targeting direct measurement of physiological signals similar to CardioMEMS. It is a direct competitor in the implantable hemodynamic monitoring category.
- Vectorious Medical Technologies: Vectorious is developing the V-LAP, an implantable left atrial pressure sensor for heart failure management. It targets the same clinical use case as CardioMEMS—remote hemodynamic monitoring to prevent heart failure decompensation—and represents a direct competitive threat.
Emerging players
- Sensible Medical Innovations: Sensible Medical develops the SensiVest, a non-invasive wearable vest that uses RF signals to monitor lung fluid in heart failure patients. It is an emerging competitor in remote heart failure monitoring that bypasses the surgical implantation requirement of CardioMEMS.
- V-Wave Ltd. V-Wave is developing interatrial shunt devices for heart failure with reduced ejection fraction. It is an emerging player in the advanced heart failure interventional space, addressing the same patient population served by CardioMEMS but via a different therapeutic mechanism.
Others
- Abbott (HeartMate 3): Abbott Laboratories is CardioMEMS's parent company and integrates the CardioMEMS HF System with HeartMate 3 LVAD within its broader heart failure portfolio. While not an external competitor, it represents the strategic channel and distribution partner through which CardioMEMS reaches the market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
CardioMEMS social profiles
Digital presenceCardioMEMS financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardioMEMS leadership team
Management profileNumber of profiles
Profiles3 records
CardioMEMS funding detail
Funding detailFunding overview
Funding rounds10 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardioMEMS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardioMEMS
What does CardioMEMS do?
CardioMEMS develops and manufactures the CardioMEMS HF System, an FDA-approved wireless implantable pulmonary artery (PA) pressure sensor that, together with a Patient Electronics System and the Merlin.net Patient Care Network portal, enables remote hemodynamic monitoring of NYHA Class II/III heart failure patients (both HFpEF and HFrEF). The system transmits PA pressure and heart rate data from the patient's home to clinicians, supporting presymptomatic intervention to reduce heart failure hospitalizations and mortality. CardioMEMS sells the platform to hospitals, cardiology practices, and heart failure centers through Abbott's cardiovascular division and is reimbursed by Medicare and Medicare Advantage.
Is CardioMEMS a public or private company?
CardioMEMS is a private company. It is classified as corporate owned and is currently acquired.
When was CardioMEMS founded?
CardioMEMS was founded in 2014. It employs 101 to 250 people.
Where is CardioMEMS based?
CardioMEMS is headquartered in Atlanta, United States, in the North America region.
How does CardioMEMS make money?
Three revenue lines are on record. Implantable Device Sales are the primary driver. The others are remote Monitoring Services and clinical Procedure Revenue.
Who are CardioMEMS's main competitors?
Broad incumbents on record are Medtronic, Edwards Lifesciences, GE HealthCare and Boston Scientific. Direct peers are Endotronix, FIRE1 (Foundry Innovation & Research 1) and Vectorious Medical Technologies. Emerging players are Sensible Medical Innovations and V-Wave Ltd.. Abbott (HeartMate 3) is listed as an others.
Does CardioMEMS have an API?
No public API is recorded for CardioMEMS.
What industry is CardioMEMS in?
CardioMEMS's product category is Implantable Cardiac Hemodynamic Monitoring Devices. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 334510 and its SIC code is 3841.